A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease
Preprint
- 17 April 2020
- preprint
- review article
- Published by Cold Spring Harbor Laboratory
Abstract
The duration and nature of immunity generated in response to SARS-CoV-2 infection is unknown. Many public health responses and modeled scenarios for COVID-19 outbreaks caused by SARS-CoV-2 assume that infection results in an immune response that protects individuals from future infections or illness for some amount of time. The timescale of protection is a critical determinant of the future impact of the pathogen. The presence or absence of protective immunity due to infection or vaccination (when available) will affect future transmission and illness severity. The dynamics of immunity and nature of protection are relevant to discussions surrounding therapeutic use of convalescent sera as well as efforts to identify individuals with protective immunity. Here, we review the scientific literature on antibody immunity to coronaviruses, including SARS-CoV-2 as well as the related SARS-CoV-1, MERS-CoV and human endemic coronaviruses (HCoVs). We reviewed 1281 abstracts and identified 322 manuscripts relevant to 5 areas of focus: 1) antibody kinetics, 2) correlates of protection, 3) immunopathogenesis, 4) antigenic diversity and cross-reactivity, and 5) population seroprevalence. While studies of SARS-CoV-2 are necessary to determine immune responses to it, evidence from other coronaviruses can provide clues and guide future research.Keywords
Other Versions
- Published version: Version Nature Communications, 11, preprints
This publication has 99 references indexed in Scilit:
- The dominance of human coronavirus OC43 and NL63 infections in infantsJournal of Clinical Virology, 2012
- The Pediatric Burden of Human Coronaviruses Evaluated for Twenty YearsThe Pediatric Infectious Disease Journal, 2009
- Examination of seroprevalence of coronavirus HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virusJournal of Clinical Virology, 2009
- Development of a Nucleocapsid-Based Human Coronavirus Immunoassay and Estimates of Individuals Exposed to Coronavirus in a U.S. Metropolitan PopulationClinical and Vaccine Immunology, 2008
- Long‐Term Care Facilities: A Cornucopia of Viral PathogensJournal of the American Geriatrics Society, 2008
- A line immunoassay utilizing recombinant nucleocapsid proteins for detection of antibodies to human coronavirusesDiagnostic Microbiology and Infectious Disease, 2008
- Seroepidemiology of group I human coronaviruses in childrenJournal of Clinical Virology, 2007
- Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodiesProceedings of the National Academy of Sciences of the United States of America, 2007
- Recombinant Protein-Based Assays for Detection of Antibodies to Severe Acute Respiratory Syndrome Coronavirus Spike and Nucleocapsid ProteinsClinical and Vaccine Immunology, 2007
- The time course of the immune response to experimental coronavirus infection of manEpidemiology and Infection, 1990